Astellas Pharma Inc. ADR (ALPMY)
OTC PINK OTC PINK Primary 
Astellas collaborates with Vir to develop its experimental prostate cancer drug
Japan's Astellas and Vir Biotechnology said on Monday they will together develop and commercialize the U.S. drug developer's prostate cancer experimental drug.
Astellas Pharma Inc. (ALPMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Astellas Pharma Inc. (ALPMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Is Alpha Cognition Inc. (ACOG) Outperforming Other Medical Stocks This Year?
Here is how Alpha Cognition Inc. (ACOG) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
Here is how Astellas Pharma Inc. (ALPMY) and AtriCure (ATRC) have performed compared to their sector so far this year.
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
Here is how Astellas Pharma Inc. (ALPMY) and AtriCure (ATRC) have performed compared to their sector so far this year.
Here's Why Astellas Pharma (ALPMY) Is a Great 'Buy the Bottom' Stock Now
Astellas Pharma (ALPMY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Astellas Pharma (ALPMY) Upgraded to Strong Buy: What Does It Mean for the Stock?
Astellas Pharma (ALPMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?
Here is how Astellas Pharma Inc. (ALPMY) and AngioDynamics (ANGO) have performed compared to their sector so far this year.
Should Value Investors Buy Astellas Pharma (ALPMY) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Astellas: Can The Gastric Cancer Approval Be The Inflection Point?
Astellas: Can The Gastric Cancer Approval Be The Inflection Point?
FDA approves Astellas' gastric cancer therapy
The U.S. Food and Drug Administration approved Astellas' gastric cancer therapy, the health regulator's website showed on Friday.
Are Investors Undervaluing Astellas Pharma (ALPMY) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
